iOnctura
6 known investors
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.
Founders & leadership
Investors Β· 6
Frequently asked questions
- What does iOnctura do?
- iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer. It serves oncology patients through low-toxicity therapies aimed at extending healthspan.
- Who founded iOnctura?
- iOnctura was founded by Catherine Pickering, Lars van der Veen.
- Who are iOnctura's investors?
- iOnctura's investors include Syncona, Inkef, 3B Future Health Fund, M Ventures, VI Partners, XGEN Venture.